© Copyright 2009 by the American Association for Clinical Chemistry Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals With and Without Diabetes: Individuals from the Copenhagen General Population Study Anne Langsted and Børge G. Nordestgaard March © Copyright 2011 by the American Association for Clinical Chemistry Journal Club

© Copyright 2009 by the American Association for Clinical Chemistry Introduction  Diabetics have higher risk of atherosclerotic cardiovascular disease than nondiabetics  Lipid derangements in diabetics High plasma triglycerides Low HDL cholesterol (High LDL cholesterol)

© Copyright 2009 by the American Association for Clinical Chemistry Introduction  Fasting or nonfasting lipid measurements A controversial subject >In the general population Concentrations of lipids, lipoproteins and apolipoproteins only differ minimally in fasting and nonfasting samples >For diabetics Presently unknown The objective of this study

© Copyright 2009 by the American Association for Clinical Chemistry Questions  What are the main mechanisms for developing atherosclerotic cardiovascular disease?  Why do diabetics have a particularly high risk of developing atherosclerotic cardiovascular disease?

© Copyright 2009 by the American Association for Clinical Chemistry Materials and methods  Copenhagen General Population Study Participants randomly selected from the general population of Copenhagen, Denmark Total participants between 2003 and 2009 N= With diabetes (self-reported, taking insulin or other antidiabetic medication, random plasma glucose >11 mmol/L) N= 2270 Denmark

© Copyright 2009 by the American Association for Clinical Chemistry Materials and methods  Analyses Fresh blood samples collected at Copenhagen University Hospital Standard hospital assays (Konelab) used to measure glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B and albumin Non-HDL cholesterol = total cholesterol – HDL cholesterol If triglycerides <4 mmol/L, LDL cholesterol was calculated by the Friedewald equation

© Copyright 2009 by the American Association for Clinical Chemistry Materials and methods  Statistical analyses All analyses performed using Stata 10. Student t-tests were used to identify differences in lipids, lipoproteins, apolipoproteins and albumin as a function of time since the last meal. All t-tests were corrected for multiple comparison with the Bonferroni method.

© Copyright 2009 by the American Association for Clinical Chemistry Questions  What are the criteria for a fasting blood sample? Are you allowed to drink anything before the sample is taken?

© Copyright 2009 by the American Association for Clinical Chemistry Results

Results

Results

Questions  What would be the advantages of measuring lipid profiles in the nonfasting state? How could this be implemented?

© Copyright 2009 by the American Association for Clinical Chemistry Discussion Mean plasma triglycerides only increased a maximum of 0.2 mmol/L after normal food intake in both diabetic and nondiabetic individuals Reduction in LDL cholesterol observed after normal food intake in both diabetic and nondiabetic individuals most likely caused by hemodilution due to fluid intake Apolipoprotein B concentrations did not change after normal food intake Non-HDL cholesterol was found to be quite stable Conclusions

© Copyright 2009 by the American Association for Clinical Chemistry Discussion Still controversial whether lipid profiles should be measured fasting or nonfasting; present data suggest that nonfasting samples can be used in diabetics and nondiabetics alike Nonfasting blood sampling would simplify the process for both patients and general practitioners/hospitals In Denmark: nonfasting lipid measurements as a standard is recommended by the Danish Society for Clinical Biochemistry - and by 2010 implemented in most of the country In Denmark: if nonfasting triglycerides are >4 mmol/L, the clinician can choose to measure triglycerides fasting. However, most do not use this option.

© Copyright 2009 by the American Association for Clinical Chemistry Discussion  Editorial by Gerald F Watts and Jeffrey S Cohn: Distinctions between screening, assessment, and treatment For initial screening for dyslipidemia, nonfasting blood samples are sufficient Recommend a fasting sample as the benchmark for risk assessment, diagnosis, and therapy of lipid disorders - with consideration given to nonfasting samples in specific clinical circumstances like stable drug therapy